Ono Pharma Foundation
Ono Pharma Foundation

Ono Pharma Foundation will be considering research proposals that exhibit the potential to transform human health. Applications comprising laboratory investigation will be considered.

Eligibility


Applicants must meet the following requirements. LOIs and final Proposals from applicants not meeting the requirements listed below will not be considered.

1
Each PI applying chemical biology area must be working in one of the nominating institutions. Nominating institutions might be replaced or added to in subsequent years.
2
Each PI applying oligonucleotide medicine research area must be working in the United States or Canada.
3
The PI must have a MD and/or a PhD degree.
4
The PI may not already be engaged in other sponsored research with Ono Pharmaceutical Co., Ltd. and/or grant program with Ono Pharma Foundation.
5
The PI may not apply for funding to amplify current work. However, PIs may research a new idea based on a prior findings of the PI.

As a US private foundation, Ono Pharma Foundation grants to Canadian institutions are conditioned on an equivalency determination by the Foundation. This may require additional documentation and information from the institution outside of the application process.

Criteria


Applications will be assessed and awards will be made based upon the following criteria:

Scientific Merit

SCIENTIFIC MERIT

Will be evaluated based on its scientific merit of the research proposal.

Relevant to our Mission

RELEVANT TO OUR MISSION

The application will be evaluated based on its relevance to Ono Pharma Foundation's mission: significance, innovation and approach.

Technical Consideration

TECHNICAL CONSIDERATIONS

Proposals will be judged on its consideration and understanding of the technology required for completion

Qualifications

QUALIFICATIONS

Principle Investigators will need to prove their relevant experience and qualifications.

Research Environment

RESEARCH ENVIRONMENT

Evidence will need to be provided of a suitable environment to conduct study.
 

Timeline


There are two steps to the application process. Learn more about the RULES.

  1. Letter of Interest ("LOI") must be submitted by all nominated, interested, and eligible PIs.
  2. A full Proposal must be submitted by invited PIs.

The timetable for both steps of the Application Process is outlined below in detail.

December 3, 2018

Funding Opportunity Program Announcement for 2019 Awards

Responsible Party: Ono Pharma Foundation

December 3, 2018

LOI submission open

Responsible Party: Ono Pharma Foundation

February 28, 2019, 5pm ET *

LOI submission due date

Responsible Party: PI/ Institution

May 1, 2019

Request for Proposal (“RFP”) sent out

Responsible Party: Ono Pharma Foundation

May 23, 2019, 5pm ET *

Proposal due date

Responsible Party: PI

July 15, 2019

Announcement of the Awards

Responsible Party: Ono Pharma Foundation

August - October, 2019

Project Start

Responsible Party: PI

*Addenda, supplemental materials, changes, or updates will not be accepted after the deadline for submitting either the LOI or the Proposal.

**As a US private foundation, Ono Pharma Foundation grants to Canadian institutions are conditioned on an equivalency determination by the Foundation. This may require additional documentation and information from the institution outside of the application process.

Brief reports will be required every six months after the granting of the Award. These reports will be a means for assuring that the research follows the approved Proposal in content and timeframe. A final study report will be due two months after Project completion.

Selection Committee: Review of LOIs, final Proposals, and selection of Awardees will be carried out by a Scientific Advisory Board (“SAB”) made up of experts from the previously identified science fields but external to Ono and the Ono Pharma Foundation.

  • Note: All submitted material will be kept strictly confidential. The selected final Proposals will be attached to the Award document and to an agreement with the Nominating Institution.
  • A preliminary review of submissions will be carried out by the Ono Pharma Foundation to ensure proposals fall within the scope of research areas and that there are no obvious concerns with the proposed research. If concerns are identified, the Proposal may not be accepted prior to evaluation by the SAB.
  • Note: Members of the SAB are not eligible to apply for an Award. Serving as a mentor, however, to a PI/ Applicant is permitted/encouraged.

Press


November 30, 2018

2019 Annual Symposium

Ono Pharma Foundation organizes an annual symposium where research scientists are given the opportunity to present their research findings and encourage scientific exchanges to accelerate advancements in the field and promote open scientific dialogue.

Date: July 1st, 2019

Location: Boston

July 31, 2018

The 2018 awardees

Congratulations!

  • Michelle Arkin, PhD, University of California – San Francisco
    • Stabilizing 14-3-3 Protein-protein interactions with small molecules
  • William Mobley, MD, PhD, University of California – San Diego
    • Selective Neuronal Delivery of ASOs Targeting APP
  • Matthew Simon, PhD, Yale University
    • Transcriptome-wide discovery of small molecule binding sites in RNA
  • Jack Taunton, PhD, University of California – San Francisco
    • Chemoproteomic technology for the direct identification of druggable protein nucleophiles
  • Christina Woo, PhD, Harvard University
    • Discovery of novel small molecule-protein interactions

May 17, 2018

2018 Annual Symposium

Date: July 9th, 2018

Location: Menlo Park, CA 94025

For more information and registration, please visit our symposium website.

November 8, 2017

The 2017 awardees

Congratulations!

  • Lingyin Li, PhD, Stanford University
    • Chemical biology of anti-cancer innate immunity
  • David Liu, PhD, Broad Institute of Harvard and MIT
    • Expanding the scope of base editing
  • Angela Koehler, PhD, Massachusetts Institute of Technology
    • Chemical probes for transcription
  • Bridget Wagner, PhD, Broad Institute of Harvard and MIT
    • Development of predictive signatures of drug toxicity and side effects using cell-based profiling
  • Jonathan Watts, PhD, University of Massachusetts -Medical School
    • Development of next-generation antisense oligonucleotides for potent gene silencing in the lung

October 1, 2017

OTS meeting

Brief introduction about the Ono Pharma Foundation was made in the 2017 OTS meeting in Bordeaux, France in September 2017.